Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17582596 | 0.86 | PTGS1 (0.48) | SMN1; SMN2POLBTDP1F2RL3KMT2A | |
| SCHEMBL17582620 | 0.82 | PTGS1 (0.57) | SMN1; SMN2POLBMAPTPTGS1MAPK1 | |
| SCHEMBL17596672 | 0.82 | TDP1 (0.51) | SMN1; SMN2TDP1KMT2AMAPTMAPK1 | |
| SCHEMBL15920987 | 0.79 | SMN1; SMN2 (0.61) | SMN1; SMN2POLBTDP1F2RL3KMT2A | |
| SCHEMBL25604982 | 0.78 | MAPK1 (0.52) | SMN1; SMN2POLBTDP1F2RL3KMT2A | |
| SCHEMBL21332805 | 0.77 | SMN1; SMN2 (0.77) | SMN1; SMN2POLBTDP1KMT2AMAPT | |
| SCHEMBL553848 | 0.77 | ALDH1A1 (0.60) | SMN1; SMN2TDP1F2RL3MAPK1CYP19A1 | |
| SCHEMBL4957675 | 0.77 | EGFR (0.49) | SMN1; SMN2POLBTDP1F2RL3KMT2A | |
| SCHEMBL29355967 | 0.76 | HDAC3 (0.52) | SMN1; SMN2POLBTDP1KMT2APTGS1 | |
| SCHEMBL13495282 | 0.76 | SMN1; SMN2 (0.61) | SMN1; SMN2POLBTDP1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191491-B1 | PYRIDAZINONE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-09-04 | — | — | EP | disclosed |
| EP-3191491-B1 | PYRIDAZINONE DERIVATIVES AS PHOSPHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARM SPA (IT) | 2019-09-04 | — | — | EP | disclosed |
| US-9745308-B2 | Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-08-29 | — | — | US | disclosed |
| US-9745308-B2 | Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-08-29 | — | — | US | disclosed |
| US-9745308-B2 | Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-08-29 | — | — | US | disclosed |
| US-20160075710-A1 | PYRIDAZINONE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-03-17 | — | — | US | disclosed |
| US-20160075710-A1 | PYRIDAZINONE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075710-A1 | PYRIDAZINONE DERIVATIVES AS PHOSHOINOSITIDE 3-KINASES INHIBITORS | PIP4K2B, PIP5K1B, PIK3CA | SMN1; SMN2 3570/4885POLB 896/4885TDP1 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.